RESUMO
We studied the characteristics of quality of life in patients in the acute and recovery phase of ischemic stroke in the vertebral-basilar basin due to hypertensive disease as the leading risk factor for the disease. The rates of basic daily activities on a Barthel scale, cognitive functions on the MMSE, physical and mental components of health on the SF-36 were significantly reduced in patients with acute ischemic stroke. The improvement in functional and cognitive impairments was observed during the first year after stroke. Parameters of quality of life improved but did not reach the control levels. The sanatorium treatment of post stroke patients significantly (p<0.05) promoted the restoration of lost functions as well as quality of life compared to outpatient rehabilitation.
Assuntos
Encéfalo/irrigação sanguínea , Transtornos Cognitivos/reabilitação , Hipertensão/complicações , Reabilitação do Acidente Vascular Cerebral , Artéria Basilar/fisiopatologia , Transtornos Cognitivos/etiologia , Transtornos Cognitivos/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Qualidade de Vida , Acidente Vascular Cerebral/etiologia , Acidente Vascular Cerebral/fisiopatologia , Inquéritos e QuestionáriosRESUMO
The results of the multicenter open-label observational study of the efficacy and safety of the Melaxen (melatonin) for the treatment of disordered sleep in patients with chronic cerebral ischemia are presented. 2062 patients were studied with the use of subjective psychometric scales: subjective sleep characteristics scale, sleep apnea screening questionnaire, Epworth sleepiness scale, hospital anxiety and depression scale. Mean age of patients was 55.7±9.0 years, there were 74.1% females and 25.9% males. Melaxen was given in dosage of 3 mg. before sleep for 24 days. The use of Melaxen leads to the increase of subjective sleep quality by the subjective sleep characteristics scale from 19.7±3.1 points to и 22.7±3.4 points on day 14 and 22.7±3.4 on day 24 (differences are significant at p<0.0001). There was the decrease of the relative number of patients with frequent night awakenings, prolonged sleep latency, short night sleep, poor quality of morning awakening and multiple bothering dreams. Authors conclude that the use of Melaxen in dosage of 3 mg before sleep is effective and safe insomnia treatment in patients with chronic cerebral ischemia.
Assuntos
Isquemia Encefálica/complicações , Melatonina/uso terapêutico , Distúrbios do Início e da Manutenção do Sono/complicações , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Feminino , Humanos , Masculino , Melatonina/administração & dosagem , Melatonina/efeitos adversos , Pessoa de Meia-IdadeRESUMO
Pelvic dysfunction is a frequent severe manifestation of multiple sclerosis (MS). Basing on the experience in management of 70 MS patients with pelvic affection, we developed an algorithm of outpatient care for such patients which involves neurological, urological and gastroenterological assistence.
Assuntos
Assistência Ambulatorial/métodos , Esclerose Múltipla/terapia , Transtornos Urinários/terapia , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/complicações , Transtornos Urinários/etiologiaRESUMO
Effect of phenotropil in combination with anticonvulsant drugs on the course of different forms of epilepsy and EEG parameters has been studied. Patients of a main group (31 patients) received phenotropil, along with antiepileptic drugs (AEP), in dosage 100 mg daily during 2 months. Effect of the therapy was compared to the patients of comparison group (30 patients) treated with AEP only. In the main group, the significant decrease of seizures and positive changes on the EEG with the reduction of the index of epileptiform changes was observed.
